2021-000567-77
A study to evaluate the safety and tolerability and to assess blood levels of seltorexant in adolescents with Major Depressive Disorder who have not responded well to their current antidepressant and psychotherapy
Janssen-Cilag International NV·EU Clinical Trials Register
Study focus
- Disease/Condition
- Major Depressive Disorder
Sponsor & location
- Primary sponsor
- Janssen-Cilag International NV
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Any potential participant who meets any of the following criteria will be excluded from participating in the study:
ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2021-000567-77
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2021-000567-77 through Pure Global AI's free database. This phase not specified trial is sponsored by Janssen-Cilag International NV and is currently status unknown. The study focuses on Major Depressive Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.